Progress toward a group B streptococcal vaccine

References

• Kobayashi M, Vekemans J, Baker CJ, Ratner AJ, Le Doare K, Schrag SJ. Group B streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. F1000Res. 2016;5:2355. doi:10.12688/f1000research.9363.1.
   PubMedGoogle Scholar
• Kobayashi M, Schrag SJ, Alderson MR, Madhi SA, Baker CJ, Sobanjo-Ter Meulen A, Kaslow DC, Smith PG, Moorthy VS, Vekemans J. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016. Vaccine. 2016;16:31236–1. doi:10.1016/j.vaccine.2016.12.029.
   PubMedGoogle Scholar
• Kwatra G, Cunnington MC, Merrall E, Adrian PV, Ip M, Klugman KP, Tam WH, Madhi SA. Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:1076–84. doi:10.1016/S1473-3099(16)30055-X.
   PubMed Web of Science ®Google Scholar
• Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis. 2001;33:556–61. doi:10.1086/322696.
   PubMed Web of Science ®Google Scholar
• Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ. 1992;41:25–32.
   PubMedGoogle Scholar
• Centers for Disease C, Prevention. Early-onset and late-onset neonatal group B streptococcal disease–United States, 1996–2004. MMWR Morb Mortal Wkly Rep. 2005;54:1205–8.
   PubMedGoogle Scholar
• Centers for Disease C, Prevention. Perinatal group B streptococcal disease after universal screening recommendations–United States, 2003–2005. MMWR Morb Mortal Wkly Rep. 2007;56:701–5.
   PubMedGoogle Scholar
• Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, Craig AS, Schaffner W, Zansky SM, Gershman K, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA. 2008;299:2056–65. doi:10.1001/jama.299.17.2056.
   PubMed Web of Science ®Google Scholar
• Jordan HT, Farley MM, Craig A, Mohle-Boetani J, Harrison LH, Petit S, Lynfield R, Thomas A, Zansky S, Gershman K, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J. 2008;27:1057–64. doi:10.1097/INF.0b013e318180b3b9.
   PubMed Web of Science ®Google Scholar
• Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. Clin Microbiol Infect. 2011;17:1294–303. doi:10.1111/j.1469-0691.2011.03576.x.
   PubMed Web of Science ®Google Scholar
• Van Dyke MK, Phares CR, Lynfield R, Thomas AR, Arnold KE, Craig AS, Mohle-Boetani J, Gershman K, Schaffner W, Petit S, et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med. 2009;360:2626–36. doi:10.1056/NEJMoa0806820.
   PubMed Web of Science ®Google Scholar
• Nuccitelli A, Rinaudo CD, Maione D. group B streptococcus vaccine: state of the art. Ther Adv Vaccines. 2015;3:76–90. doi:10.1177/2051013615579869.
   PubMedGoogle Scholar
• Edward MS, Nizet V, Baker CJ. Group B streptococcal infection. In: Remington JS, Klien JO, Baker CJ, Wilson CB, eds. Infectious diseases of the fetus and newborn infant,. Philadelphia: WB Saunders Co, 2006:1091–141.
   Google Scholar
• Berardi A, Rossi C, Lugli L, Creti R, Bacchi Reggiani ML, Lanari M, Memo L, Pedna MF, Venturelli C, Perrone E, et al. Group B streptococcus late-onset disease: 2003–2010. Pediatrics. 2013;131:e361–8. doi:10.1542/peds.2012-1231.
   PubMed Web of Science ®Google Scholar
• Pena BM, Harper MB, Fleisher GR. Occult bacteremia with group B streptococci in an outpatient setting. Pediatrics. 1998;102:67–72. doi:10.1542/peds.102.1.67.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Oh KY, Kim MY, Seo YS, Shin JH, Song YR, Yang JH, Foxman B, Ki M. Risk factors for group B streptococcus colonization among pregnant women in Korea. Epidemiol Health. 2011;33:e2011010. doi:10.4178/epih/e2011010.
   PubMedGoogle Scholar
• Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, Madrid L, Blencowe H, Cousens S, Baker CJ, et al. Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis. 2017;65:S200–S19. doi:10.1093/cid/cix664.
   PubMed Web of Science ®Google Scholar
• Le Doare K, Heath PT. An overview of global GBS epidemiology. Vaccine. 2013;31:D7–D12. doi:10.1016/j.vaccine.2013.01.009.
   PubMed Web of Science ®Google Scholar
• Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis. 2005;41:839–47. doi:10.1086/432804.
   PubMed Web of Science ®Google Scholar
• Sendi P, Johansson L, Norrby-Teglund A. Invasive group B streptococcal disease in non-pregnant adults – A review with emphasis on skin and soft-tissue infections. Infection. 2008;36:100–11. doi:10.1007/s15010-007-7251-0.
   PubMed Web of Science ®Google Scholar
• Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci. 2013;28:4–15. doi:10.3346/jkms.2013.28.1.4.
   PubMed Web of Science ®Google Scholar
• Berg S, Trollfors B, Lagergard T, Zackrisson G, Claesson BA. Serotypes and clinical manifestations of group B streptococcal infections in western Sweden. Clin Microbiol Infect. 2000;6:9–13. doi:10.1046/j.1469-0691.2000.00007.x.
   PubMed Web of Science ®Google Scholar
• Martins ER, Pessanha MA, Ramirez M, Melo-Cristino J, Portuguese Group for the Study of Streptococcal I. Analysis of group B streptococcal isolates from infants and pregnant women in Portugal revealing two lineages with enhanced invasiveness. J Clin Microbiol 2007; 45:3224–9. doi:10.1128/JCM.01182-07.
   PubMed Web of Science ®Google Scholar
• Bisharat N, Jones N, Marchaim D, Block C, Harding RM, Yagupsky P, Peto T, Crook DW. Population structure of group B streptococcus from a low-incidence region for invasive neonatal disease. Microbiology. 2005;151:1875–81. doi:10.1099/mic.0.27826-0.
   PubMed Web of Science ®Google Scholar
• Madzivhandila M, Adrian PV, Cutland CL, Kuwanda L, Schrag SJ, Madhi SA. Serotype distribution and invasive potential of group B streptococcus isolates causing disease in infants and colonizing maternal-newborn dyads. PloS One. 2011;6:e17861. doi:10.1371/journal.pone.0017861.
   PubMed Web of Science ®Google Scholar
• Ip M, Ang I, Fung K, Liyanapathirana V, Luo MJ, Lai R. Hypervirulent Clone of group B streptococcus Serotype III Sequence Type 283, Hong Kong, 1993–2012. Emerg Infect Dis. 2016;22:1800–3. doi:10.3201/eid2210.151436.
   PubMed Web of Science ®Google Scholar
• Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. 2002;51:1–22.
   PubMedGoogle Scholar
• Yoon IA, Jo DS, Cho EY, Choi EH, Lee HJ, Lee H. Clinical significance of serotype V among infants with invasive group B streptococcal infections in South Korea. Int J Infect Dis. 2015;38:136–40. doi:10.1016/j.ijid.2015.05.017.
   PubMed Web of Science ®Google Scholar
• Lu B, Chen X, Wang J, Wang D, Zeng J, Li Y, Li D, Zhu F, Cui Y, Huang L. Molecular characteristics and antimicrobial resistance in invasive and noninvasive group B streptococcus between 2008 and 2015 in China. Diagn Microbiol Infect Dis. 2016;86:351–7. doi:10.1016/j.diagmicrobio.2016.08.023.
   PubMed Web of Science ®Google Scholar
• Morozumi M, Wajima T, Kuwata Y, Chiba N, Sunaoshi K, Sugita K, Sakata H, Iwata S, Ubukata K. Associations between capsular serotype, multilocus sequence type, and macrolide resistance in Streptococcus agalactiae isolates from Japanese infants with invasive infections. Epidemiol Infect. 2014;142:812–9. doi:10.1017/S0950268813001647.
   PubMed Web of Science ®Google Scholar
• von Both U, Ruess M, Mueller U, Fluegge K, Sander A, Berner R. A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany. J Clin Microbiol. 2003;41:2166–9. doi:10.1128/JCM.41.5.2166-2169.2003.
   PubMed Web of Science ®Google Scholar
• Lin FY, Azimi PH, Weisman LE, Philips JB, 3rd, Regan J, Clark P, Rhoads GG, Clemens J, Troendle J, Pratt E, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995–1998. Clin Infect Dis. 2000;31:76–9. doi:10.1086/313936.
   PubMed Web of Science ®Google Scholar
• Dutra VG, Alves VM, Olendzki AN, Dias CA, de Bastos AF, Santos GO, de Amorin EL, Sousa MÂ, Santos R, Ribeiro PC, et al. Streptococcus agalactiae in Brazil: serotype distribution, virulence determinants and antimicrobial susceptibility. BMC Infect Dis. 2014;14:323. doi:10.1186/1471-2334-14-323.
   PubMed Web of Science ®Google Scholar
• Rajagopal L. Understanding the regulation of group B streptococcal virulence factors. Future Microbiol. 2009;4:201–21. doi:10.2217/17460913.4.2.201.
   PubMed Web of Science ®Google Scholar
• Herbert MA, Beveridge CJ, Saunders NJ. Bacterial virulence factors in neonatal sepsis: group B streptococcus. Curr Opin Infect Dis. 2004;17:225–9. doi:10.1097/00001432-200406000-00009.
   PubMed Web of Science ®Google Scholar
• Vornhagen J, Adams Waldorf KM, Rajagopal L. Perinatal group B streptococcal infections: Virulence factors, immunity, and prevention strategies. Trends Microbiol. 2017;25:919–31. doi:10.1016/j.tim.2017.05.013.
   PubMed Web of Science ®Google Scholar
• Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, Konradsen HB, Nahm MH. Pneumococcal capsules and their types: Past, present, and future. Clin Microbiol Rev. 2015;28:871–99. doi:10.1128/CMR.00024-15.
   PubMed Web of Science ®Google Scholar
• Croney CM, Nahm MH, Juhn SK, Briles DE, Crain MJ. Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine. Clin Vaccine Immunol. 2013;20:1711–8. doi:10.1128/CVI.00381-13.
   PubMed Web of Science ®Google Scholar
• D'Urzo N, Martinelli M, Pezzicoli A, De Cesare V, Pinto V, Margarit I, Telford JL, Maione D. Acidic pH strongly enhances in vitro biofilm formation by a subset of hypervirulent ST-17 Streptococcus agalactiae strains. Appl Environ Microbiol. 2014;80:2176–85. doi:10.1128/AEM.03627-13.
   PubMed Web of Science ®Google Scholar
• Rosini R, Margarit I. Biofilm formation by Streptococcus agalactiae: influence of environmental conditions and implicated virulence factors. Front Cell Infect Microbiol. 2015;5:6. doi:10.3389/fcimb.2015.00006.
   PubMed Web of Science ®Google Scholar
• Xia FD, Mallet A, Caliot E, Gao C, Trieu-Cuot P, Dramsi S. Capsular polysaccharide of group B streptococcus mediates biofilm formation in the presence of human plasma. Microbes Infect. 2015;17:71–6. doi:10.1016/j.micinf.2014.10.007.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Carey VJ, Rench MA, Edwards MS, Hillier SL, Kasper DL, Platt R. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis. 2014;209:781–8. doi:10.1093/infdis/jit549.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976;294:753–6. doi:10.1056/NEJM197604012941404.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Kasper DL, Tager I, Paredes A, Alpert S, McCormack WM, Goroff D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest. 1977;59:810–8. doi:10.1172/JCI108703.
   PubMed Web of Science ®Google Scholar
• Cieslewicz MJ, Chaffin D, Glusman G, Kasper D, Madan A, Rodrigues S, Fahey J, Wessels MR, Rubens CE. Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infect Immun. 2005;73:3096–103. doi:10.1128/IAI.73.5.3096-3103.2005.
   PubMed Web of Science ®Google Scholar
• Berti F, Campisi E, Toniolo C, Morelli L, Crotti S, Rosini R, Romano MR, Pinto V, Brogioni B, Torricelli G, et al. Structure of the type IX group B Streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII. J Biol Chem. 2014;289:23437–48. doi:10.1074/jbc.M114.567974.
   PubMed Web of Science ®Google Scholar
• Carboni F, Adamo R, Fabbrini M, De Ricco R, Cattaneo V, Brogioni B, Veggi D, Pinto V, Passalacqua I, Oldrini D, et al. Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide. Proc Natl Acad Sci U S A. 2017;114:5017–22. doi:10.1073/pnas.1701885114.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Miyake K, Koike Y, Watanabe M, Machida Y, Ohta M, Iijima S. Molecular characterization of type-specific capsular polysaccharide biosynthesis genes of Streptococcus agalactiae type Ia. J Bacteriol. 1999;181:5176–84.
   PubMed Web of Science ®Google Scholar
• Kolkman MA, Wakarchuk W, Nuijten PJ, van der Zeijst BA. Capsular polysaccharide synthesis in Streptococcus pneumoniae serotype 14: molecular analysis of the complete cps locus and identification of genes encoding glycosyltransferases required for the biosynthesis of the tetrasaccharide subunit. Mol Microbiol. 1997;26:197–208. doi:10.1046/j.1365-2958.1997.5791940.x.
   PubMed Web of Science ®Google Scholar
• Chaffin DO, Beres SB, Yim HH, Rubens CE. The serotype of type Ia and III group B streptococci is determined by the polymerase gene within the polycistronic capsule operon. J Bacteriol. 2000;182:4466–77. doi:10.1128/JB.182.16.4466-4477.2000.
   PubMed Web of Science ®Google Scholar
• Guttormsen HK, Baker CJ, Nahm MH, Paoletti LC, Zughaier SM, Edwards MS, Kasper DL. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun. 2002;70:1724–38. doi:10.1128/IAI.70.4.1724-1738.2002.
   PubMed Web of Science ®Google Scholar
• Carlin AF, Chang YC, Areschoug T, Lindahl G, Hurtado-Ziola N, King CC, Varki A, Nizet V. group B streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. J Exp Med. 2009;206:1691–9. doi:10.1084/jem.20090691.
   PubMed Web of Science ®Google Scholar
• Chang YC, Olson J, Beasley FC, Tung C, Zhang J, Crocker PR, Varki A, Nizet V. group B streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo. PLoS Pathog. 2014;10:e1003846. doi:10.1371/journal.ppat.1003846.
   PubMed Web of Science ®Google Scholar
• Schnaitman CA, Klena JD. Genetics of lipopolysaccharide biosynthesis in enteric bacteria. Microbiol Rev. 1993;57:655–82.
   PubMedGoogle Scholar
• Toniolo C, Balducci E, Romano MR, Proietti D, Ferlenghi I, Grandi G, Berti F, Ros IM, Janulczyk R. Streptococcus agalactiae capsule polymer length and attachment is determined by the proteins CpsABCD. J Biol Chem. 2015; 290:9521–32. doi:10.1074/jbc.M114.631499.
   PubMed Web of Science ®Google Scholar
• Hanson BR, Runft DL, Streeter C, Kumar A, Carion TW, Neely MN. Functional analysis of the CpsA protein of Streptococcus agalactiae. J Bacteriol. 2012;194:1668–78. doi:10.1128/JB.06373-11.
   PubMed Web of Science ®Google Scholar
• Cartee RT, Forsee WT, Bender MH, Ambrose KD, Yother J. CpsE from type 2 Streptococcus pneumoniae catalyzes the reversible addition of glucose-1-phosphate to a polyprenyl phosphate acceptor, initiating type 2 capsule repeat unit formation. J Bacteriol. 2005;187:7425–33. doi:10.1128/JB.187.21.7425-7433.2005.
   PubMed Web of Science ®Google Scholar
• Al-Dabbagh B, Henry X, El Ghachi M, Auger G, Blanot D, Parquet C, Mengin-Lecreulx D, Bouhss A. Active site mapping of MraY, a member of the polyprenyl-phosphate N-acetylhexosamine 1-phosphate transferase superfamily, catalyzing the first membrane step of peptidoglycan biosynthesis. Biochemistry. 2008;47:8919–28. doi:10.1021/bi8006274.
   PubMed Web of Science ®Google Scholar
• Barreteau H, Magnet S, El Ghachi M, Touze T, Arthur M, Mengin-Lecreulx D, Blanot D. Quantitative high-performance liquid chromatography analysis of the pool levels of undecaprenyl phosphate and its derivatives in bacterial membranes. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:213–20. doi:10.1016/j.jchromb.2008.12.010.
   PubMed Web of Science ®Google Scholar
• James DB, Gupta K, Hauser JR, Yother J. Biochemical activities of Streptococcus pneumoniae serotype 2 capsular glycosyltransferases and significance of suppressor mutations affecting the initiating glycosyltransferase Cps2E. J Bacteriol. 2013;195:5469–78. doi:10.1128/JB.00715-13.
   PubMed Web of Science ®Google Scholar
• Larson TR, Yother J. Streptococcus pneumoniae capsular polysaccharide is linked to peptidoglycan via a direct glycosidic bond to beta-D-N-acetylglucosamine. Proc Natl Acad Sci U S A. 2017;114:5695–700. doi:10.1073/pnas.1620431114.
   PubMed Web of Science ®Google Scholar
• Avery OT, Dubos R. The protective action of a specific enzyme against type III pneumococcus infection in mice. J Exp Med. 1931;54:73–89. doi:10.1084/jem.54.1.73.
   PubMedGoogle Scholar
• MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. JEM. 1945;82:445–65. doi:10.1084/jem.82.6.445.
   Web of Science ®Google Scholar
• Heidelberger M, Tyler JM. Cross-reactions of pneumococcal types. J Exp Med. 1964;120:711–9. doi:10.1084/jem.120.5.711.
   PubMed Web of Science ®Google Scholar
• Heidelberger M. Precipitating cross-reactions among pneumococcal types. Infect Immun. 1983;41:1234–44.
   PubMed Web of Science ®Google Scholar
• Heidelberger M, Rebers PA. Immunochemistry of the pneumococcal types II, V, and VI. The relation of type VI to type II and other correlations between chemical constitution and precipitation in antisera to type VI. J Bacteriol. 1960;80:145–53.
   PubMed Web of Science ®Google Scholar
• Heidelberger M, Bernheimer AW. Cross-reactions of polysaccharides of fungi, molds, and yeasts in anti-pneumococcal and other antisera. Proc Nat Acad Sci USA. 1984;81:5247–9. doi:10.1073/pnas.81.16.5247.
   PubMed Web of Science ®Google Scholar
• MacPherson CFC, Heidelberger M, Alexander HE, Leidy G. The specific polysaccharides of types A,B,C,D, and F Hemophilus influenzae. J Immunol. 1946;52:207–19.
   PubMed Web of Science ®Google Scholar
• Heidelberger M. A “pure” organic chemists downward path. Annu Rev Microbiol. 1977;31:1–12. doi:10.1146/annurev.mi.31.100177.000245.
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol. 2004;19:353–63. doi:10.1023/B:EJEP.0000024701.94769.98.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Edwards MS, Kasper DL. Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest. 1978;61:1107–10. doi:10.1172/JCI109011.
   PubMed Web of Science ®Google Scholar
• Kasper DL, Goroff DK, Baker CJ. Immunochemical characterization of native polysaccharides from group B streptococcus: the relationship of the type III and group B determinants. J Immunol. 1978;121:1096–105.
   PubMed Web of Science ®Google Scholar
• Basham LE, Pavliak V, Li X, Hawwari A, Kotloff KL, Edelman R, Fattom A. A simple, quantitative, reproducible avidin-biotin ELISA for the evaluation of group B streptococcus type-specific antibodies in humans. Vaccine. 1996;14:439–45. doi:10.1016/0264-410X(95)00146-R.
   PubMed Web of Science ®Google Scholar
• Larsen JW, Jr, Harper JS, 3rd, London WT, Baker CJ, Curfman BL, Kasper DL, Sever JL. Antibody to type III group B Streptococcus in the rhesus monkey. Am J Obstet Gynecol. 1983;146:958–62. doi:10.1016/0002-9378(83)90973-0.
   PubMed Web of Science ®Google Scholar
• De Cueninck BJ, Eisenstein TK, McIntosh TS, Shockman GD, Swenson RM. Quantitation of in vitro opsonic activity of human antibody induced by a vaccine consisting of the type III-specific polysaccharide of group B streptococcus. Infect Immun. 1983;39:1155–60.
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, Group WRVCE. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization Meeting held on 23–24 March 2015. Vaccine. 2016;34:190–7. doi:10.1016/j.vaccine.2015.05.093.
   PubMed Web of Science ®Google Scholar
• Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55–70 years of age. Clin Infect Dis. 2009;49:241–8. doi:10.1086/599824.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin Infect Dis. 2009;49:1318–25. doi:10.1086/606046.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis. 2003;188:66–73. doi:10.1086/375536.
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Wessels MR, Michon F, DiFabio J, Jennings HJ, Kasper DL. group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1992;60:4009–14.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME, Kasper DL. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis. 2000;182:1129–38. doi:10.1086/315839.
   PubMed Web of Science ®Google Scholar
• Wessels MR, Paoletti LC, Guttormsen HK, Michon F, D'Ambra AJ, Kasper DL. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immun. 1998;66:2186–92.
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Kasper DL. Conjugate vaccines against group B Streptococcus types IV and VII. J Infect Dis. 2002;186:123–6. doi:10.1086/341073.
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Kennedy RC, Chanh TC, Kasper DL. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons. Infect Immun. 1996;64:677–9.
   PubMed Web of Science ®Google Scholar
• Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest. 1996;98:2308–14. doi:10.1172/JCI119042.
   PubMed Web of Science ®Google Scholar
• Vekemans J, Moorthy V, Friede M, Alderson MR, Sobanjo-Ter Meulen A, Baker CJ, Heath PT, Madhi SA, Mehring-Le Doare K, Saha SK, et al. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine. 2018;17:31359–2. doi:10.1016/j.vaccine.2017.09.087.
   Google Scholar
• Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis. 1999;179:142–50. doi:10.1086/314574.
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Rench MA, Kasper DL, Molrine D, Ambrosino D, Baker CJ. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun. 2001;69:6696–701. doi:10.1128/IAI.69.11.6696-6701.2001.
   PubMed Web of Science ®Google Scholar
• Brigtsen AK, Kasper DL, Baker CJ, Jennings HJ, Guttormsen HK. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J Infect Dis. 2002;185:1277–84. doi:10.1086/340324.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child. 2003;88:375–8. doi:10.1136/adc.88.5.375.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Edwards MS, Kasper DL. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis. 2004;189:1103–12. doi:10.1086/382193.
   PubMed Web of Science ®Google Scholar
• Pannaraj PS, Edwards MS, Ewing KT, Lewis AL, Rench MA, Baker CJ. Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation. Vaccine. 2009;27:4452–6. doi:10.1016/j.vaccine.2009.05.039.
   PubMed Web of Science ®Google Scholar
• Heyderman RS, Madhi SA, French N, Cutland C, Ngwira B, Kayambo D, Mboizi R, Koen A, Jose L, Olugbosi M, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016;16:546–55. doi:10.1016/S1473-3099(15)00484-3.
   PubMed Web of Science ®Google Scholar
• Kasper DL, Wessels MR, Guttormsen HK, Paoletti LC, Edwards MS, Baker CJ. Measurement of human antibodies to type III group B Streptococcus. Infect Immun. 1999;67:4303–5.
   PubMed Web of Science ®Google Scholar
• Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, Tettelin H, Brettoni C, Iacobini ET, Rosini R, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science. 2005;309:148–50. doi:10.1126/science.1109869.
   PubMed Web of Science ®Google Scholar
• Tettelin H, Medini D, Donati C, Masignani V. Towards a universal group B Streptococcus vaccine using multistrain genome analysis. Expert Rev Vaccines. 2006;5:687–94. doi:10.1586/14760584.5.5.687.
   PubMed Web of Science ®Google Scholar
• Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M, Portuguese Surveillance Group for the Study of Respiratory P. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect. 2008;14:835–43. doi:10.1111/j.1469-0691.2008.02031.x.
   PubMed Web of Science ®Google Scholar
• Gonzalez BE, Jacobs MR. The potential of human nasal colonization with Streptococcus pneumoniae as a universal pneumococcal vaccine. Am J Respir Crit Care Med. 2013;187:794–5. doi:10.1164/rccm.201302-0361ED.
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R. Interactions of conjugate vaccines and co-administered vaccines. Hum Vaccin Immunother. 2016;12:226–30. doi:10.1080/21645515.2015.1091908.
   PubMed Web of Science ®Google Scholar
• Oliver MB, van der Linden MP, Kuntzel SA, Saad JS, Nahm MH. Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem. 2015;290:26474–5. doi:10.1074/jbc.A113.480152.
   PubMed Web of Science ®Google Scholar
• Chang B, Nariai A, Sekizuka T, Akeda Y, Kuroda M, Oishi K, Ohnishi M. Capsule switching and antimicrobial resistance acquired during repeated streptococcus pneumoniae Pneumonia episodes. J Clin Microbiol. 2015;53:3318–24. doi:10.1128/JCM.01222-15.
   PubMed Web of Science ®Google Scholar
• Lachenauer CS, Kasper DL, Shimada J, Ichiman Y, Ohtsuka H, Kaku M, Paoletti LC, Ferrieri P, Madoff LC. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis. 1999;179:1030–3. doi:10.1086/314666.
   PubMed Web of Science ®Google Scholar
• Persson E, Berg S, Trollfors B, Larsson P, Ek E, Backhaus E, Claesson BE, Jonsson L, Rådberg G, Ripa T, et al. Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998–2001. Clin Microbiol Infect. 2004;10:791–6. doi:10.1111/j.1469-0691.2004.00931.x.
   PubMed Web of Science ®Google Scholar
• Yao K, Poulsen K, Maione D, Rinaudo CD, Baldassarri L, Telford JL, Sørensen UB; Members of the DEVANI Study Group, Kilian M. Capsular gene typing of Streptococcus agalactiae compared to serotyping by latex agglutination. J Clin Microbiol. 2013;51:503–7. doi:10.1128/JCM.02417-12.
   PubMed Web of Science ®Google Scholar
• Ramaswamy SV, Ferrieri P, Flores AE, Paoletti LC. Molecular characterization of nontypeable group B streptococcus. J Clin Microbiol. 2006;44:2398–403. doi:10.1128/JCM.02236-05.
   PubMed Web of Science ®Google Scholar
• Grandi G. Bacterial surface proteins and vaccines. F1000 Biol Rep. 2010;2:36.
   PubMedGoogle Scholar
• Rodriguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, Scarselli M, Doro F, Ferrari G, Garaguso I, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol. 2006;24:191–7. doi:10.1038/nbt1179.
   PubMed Web of Science ®Google Scholar
• Raynes JM, Young PG, Proft T, Williamson DA, Baker EN, Moreland NJ. Protein adhesins as vaccine antigens for Group A Streptococcus. Pathog Dis. 2018;76:fly061. doi:10.1093/femspd/fty016.
   PubMed Web of Science ®Google Scholar
• Navarre WW, Schneewind O. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev. 1999;63:174–229.
   PubMed Web of Science ®Google Scholar
• Hughes MJ, Moore JC, Lane JD, Wilson R, Pribul PK, Younes ZN, Dobson RJ, Everest P, Reason AJ, Redfern JM, et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun. 2002;70:1254–9. doi:10.1128/IAI.70.3.1254-1259.2002.
   PubMed Web of Science ®Google Scholar
• Lindahl G, Stalhammar-Carlemalm M, Areschoug T. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev. 2005;18:102–27. doi:10.1128/CMR.18.1.102-127.2005.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang S, Shen Z, Ren G, Liu L, Ma Y, Zhang Y, Wang W. Development of a vaccine against Streptococcus agalactiae in fish based on truncated cell wall surface anchor proteins. Vet Rec. 2016;179:359. doi:10.1136/vr.103692.
   PubMed Web of Science ®Google Scholar
• Gabrielsen C, Maeland JA, Lyng RV, Radtke A, Afset JE. Molecular characteristics of Streptococcus agalactiae strains deficient in alpha-like protein encoding genes. J Med Microbiol. 2017;66:26–33. doi:10.1099/jmm.0.000412.
   PubMed Web of Science ®Google Scholar
• Maeland JA, Afset JE, Lyng RV, Radtke A. Survey of immunological features of the alpha-like proteins of Streptococcus agalactiae. Clin Vaccine Immunol. 2015;22:153–9. doi:10.1128/CVI.00643-14.
   PubMed Web of Science ®Google Scholar
• Baron MJ, Bolduc GR, Goldberg MB, Auperin TC, Madoff LC. Alpha C protein of group B Streptococcus binds host cell surface glycosaminoglycan and enters cells by an actin-dependent mechanism. J Biol Chem. 2004;279:24714–23. doi:10.1074/jbc.M402164200.
   PubMed Web of Science ®Google Scholar
• Jerlstrom PG, Talay SR, Valentin-Weigand P, Timmis KN, Chhatwal GS. Identification of an immunoglobulin A binding motif located in the beta-antigen of the c protein complex of group B streptococci. Infect Immun. 1996;64:2787–93.
   PubMed Web of Science ®Google Scholar
• Jerlstrom PG, Chhatwal GS, Timmis KN. The IgA-binding beta antigen of the c protein complex of Group B streptococci: sequence determination of its gene and detection of two binding regions. Mol Microbiol. 1991;5:843–9. doi:10.1111/j.1365-2958.1991.tb00757.x.
   PubMed Web of Science ®Google Scholar
• Jarva H, Hellwage J, Jokiranta TS, Lehtinen MJ, Zipfel PF, Meri S. The group B streptococcal beta and pneumococcal Hic proteins are structurally related immune evasion molecules that bind the complement inhibitor factor H in an analogous fashion. J Immunol. 2004;172:3111–8. doi:10.4049/jimmunol.172.5.3111.
   PubMed Web of Science ®Google Scholar
• Stalhammar-Carlemalm M, Stenberg L, Lindahl G. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J Exp Med. 1993; 177:1593–603. doi:10.1084/jem.177.6.1593.
   PubMed Web of Science ®Google Scholar
• Gravekamp C, Kasper DL, Paoletti LC, Madoff LC. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect Immun. 1999;67:2491–6.
   PubMed Web of Science ®Google Scholar
• Michel JL, Madoff LC, Kling DE, Kasper DL, Ausubel FM. Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun. 1991;59:2023–8.
   PubMed Web of Science ®Google Scholar
• Gravekamp C, Horensky DS, Michel JL, Madoff LC. Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes. Infect Immun. 1996;64:3576–83.
   PubMed Web of Science ®Google Scholar
• Erdogan S, Fagan PK, Talay SR, Rohde M, Ferrieri P, Flores AE, Guzmán CA, Walker MJ, Chhatwal GS. Molecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococci. Infect Immun. 2002;70:803–11. doi:10.1128/IAI.70.2.803-811.2002.
   PubMed Web of Science ®Google Scholar
• Lin SM, Zhi Y, Ahn KB, Lim S, Seo HS. Status of group B streptococcal vaccine development. Clin Exp Vaccine Res. 2018;7:76–81. doi:10.7774/cevr.2018.7.1.76.
   PubMed Web of Science ®Google Scholar
• Doro F, Liberatori S, Rodriguez-Ortega MJ, Rinaudo CD, Rosini R, Mora M, Scarselli M, Altindis E, D'Aurizio R, Stella M, et al. Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for group B streptococcus hypervirulent strain COH1. Mol Cell Proteomics. 2009;8:1728–37. doi:10.1074/mcp.M800486-MCP200.
   PubMed Web of Science ®Google Scholar
• Takamatsu D, Bensing BA, Cheng H, Jarvis GA, Siboo IR, Lopez JA, Griffiss JM, Sullam PM. Binding of the Streptococcus gordonii surface glycoproteins GspB and Hsa to specific carbohydrate structures on platelet membrane glycoprotein Ibalpha. Mol Microbiol. 2005;58:380–92. doi:10.1111/j.1365-2958.2005.04830.x.
   PubMed Web of Science ®Google Scholar
• Bensing BA, Lopez JA, Sullam PM. The Streptococcus gordonii surface proteins GspB and Hsa mediate binding to sialylated carbohydrate epitopes on the platelet membrane glycoprotein Ibalpha. Infect Immun. 2004;72:6528–37. doi:10.1128/IAI.72.11.6528-6537.2004.
   PubMed Web of Science ®Google Scholar
• Sullam PM, Hyun WC, Szollosi J, Dong J, Foss WM, Lopez JA. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on the platelet plasma membrane. J Biol Chem. 1998;273:5331–6. doi:10.1074/jbc.273.9.5331.
   PubMed Web of Science ®Google Scholar
• Bensing BA, Khedri Z, Deng L, Yu H, Prakobphol A, Fisher SJ, Chen X, Iverson TM, Varki A, Sullam PM. Novel aspects of sialoglycan recognition by the Siglec-like domains of streptococcal SRR glycoproteins. Glycobiology. 2016;26:1222–34.
   PubMed Web of Science ®Google Scholar
• Seo HS, Minasov G, Seepersaud R, Doran KS, Dubrovska I, Shuvalova L, Anderson WF, Iverson TM, Sullam PM. Characterization of fibrinogen binding by glycoproteins Srr1 and Srr2 of Streptococcus agalactiae. J Biol Chem. 2013;288:35982–96. doi:10.1074/jbc.M113.513358.
   PubMed Web of Science ®Google Scholar
• Seo HS, Xiong YQ, Sullam PM. Role of the serine-rich surface glycoprotein Srr1 of Streptococcus agalactiae in the pathogenesis of infective endocarditis. PloS One. 2013;8:e64204. doi:10.1371/journal.pone.0064204.
   PubMed Web of Science ®Google Scholar
• Seo HS, Mu R, Kim BJ, Doran KS, Sullam PM. Binding of glycoprotein Srr1 of Streptococcus agalactiae to fibrinogen promotes attachment to brain endothelium and the development of meningitis. PLoS Pathog. 2012;8:e1002947. doi:10.1371/journal.ppat.1002947.
   PubMed Web of Science ®Google Scholar
• Wang NY, Patras KA, Seo HS, Cavaco CK, Rosler B, Neely MN, Sullam PM, Doran KS. Group B streptococcal serine-rich repeat proteins promote interaction with fibrinogen and vaginal colonization. J Infect Dis. 2014;210:982–91. doi:10.1093/infdis/jiu151.
   PubMed Web of Science ®Google Scholar
• Lin SM, Jang AY, Zhi Y, Gao S, Lim S, Lim JH, Song JY, Sullam PM, Rhee JH. Seo H. Vaccination With a Latch Peptide Provides Serotype-Independent Protection Against group B streptococcus Infection in Mice. J Infect Dis. 2017;217:93–102. doi:10.1093/infdis/jix565.
   PubMed Web of Science ®Google Scholar
• Chmouryguina I, Suvorov A, Ferrieri P, Cleary PP. Conservation of the C5a peptidase genes in group A and B streptococci. Infect Immun. 1996;64:2387–90.
   PubMed Web of Science ®Google Scholar
• Bohnsack JF, Takahashi S, Hammitt L, Miller DV, Aly AA, Adderson EE. Genetic polymorphisms of group B streptococcus scpB alter functional activity of a cell-associated peptidase that inactivates C5a. Infect Immun. 2000;68:5018–25. doi:10.1128/IAI.68.9.5018-5025.2000.
   PubMed Web of Science ®Google Scholar
• Brown CK, Gu ZY, Matsuka YV, Purushothaman SS, Winter LA, Cleary PP, Olmsted SB, Ohlendorf DH, Earhart CA. Structure of the streptococcal cell wall C5a peptidase. Proc Natl Acad Sci U S A. 2005;102:18391–6. doi:10.1073/pnas.0504954102.
   PubMed Web of Science ®Google Scholar
• Kagawa TF, O'Connell MR, Mouat P, Paoli M, O'Toole PW, Cooney JC. Model for substrate interactions in C5a peptidase from Streptococcus pyogenes: A 1.9 A crystal structure of the active form of ScpA. J Mol Biol. 2009;386:754–72. doi:10.1016/j.jmb.2008.12.074.
   PubMed Web of Science ®Google Scholar
• Beckmann C, Waggoner JD, Harris TO, Tamura GS, Rubens CE. Identification of novel adhesins from Group B streptococci by use of phage display reveals that C5a peptidase mediates fibronectin binding. Infect Immun. 2002;70:2869–76. doi:10.1128/IAI.70.6.2869-2876.2002.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Debol S, Lam H, Eby R, Edwards L, Matsuka Y, Olmsted SB, Cleary PP. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice. Infect Immun. 2002;70:6409–15. doi:10.1128/IAI.70.11.6409-6415.2002.
   PubMed Web of Science ®Google Scholar
• Bohnsack JF, Widjaja K, Ghazizadeh S, Rubens CE, Hillyard DR, Parker CJ, Albertine KH, Hill HR. A role for C5 and C5a-ase in the acute neutrophil response to group B streptococcal infections. J Infect Dis. 1997;175:847–55. doi:10.1086/513981.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Carlson B, Pillai S, Eby R, Edwards L, Olmsted SB, Cleary P. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun. 2001;69:2302–8. doi:10.1128/IAI.69.4.2302-2308.2001.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Stafslien D, Purushothaman SS, Cleary P. The group B streptococcal C5a peptidase is both a specific protease and an invasin. Infect Immun. 2002;70:2408–13. doi:10.1128/IAI.70.5.2408-2413.2002.
   PubMed Web of Science ®Google Scholar
• Santillan DA, Rai KK, Santillan MK, Krishnamachari Y, Salem AK, Hunter SK. Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model. Am J Obstet Gynecol. 2011;205:249 e1-8. doi:10.1016/j.ajog.2011.06.024.
   PubMed Web of Science ®Google Scholar
• Santillan DA, Andracki ME, Hunter SK. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase. Am J Obstet Gynecol. 2008;198:114 e1-6. doi:10.1016/j.ajog.2007.06.003.
   PubMed Web of Science ®Google Scholar
• Tettelin H, Masignani V, Cieslewicz MJ, Donati C, Medini D, Ward NL, Angiuoli SV, Crabtree J, Jones AL, Durkin AS, et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial “pan-genome”. Proc Natl Acad Sci U S A. 2005;102:13950–5. doi:10.1073/pnas.0506758102.
   PubMed Web of Science ®Google Scholar
• Lauer P, Rinaudo CD, Soriani M, Margarit I, Maione D, Rosini R, Taddei AR, Mora M, Rappuoli R, Grandi G, et al. Genome analysis reveals pili in group B streptococcus. Science. 2005;309:105. doi:10.1126/science.1111563.
   PubMed Web of Science ®Google Scholar
• Rosini R, Rinaudo CD, Soriani M, Lauer P, Mora M, Maione D, Taddei A, Santi I, Ghezzo C, Brettoni C, et al. Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol. 2006;61:126–41. doi:10.1111/j.1365-2958.2006.05225.x.
   PubMed Web of Science ®Google Scholar
• Margarit I, Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, Buttazzoni E, Rosini R, Runci Y, Mora M, Buccato S, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis. 2009;199:108–15. doi:10.1086/595564.
   PubMed Web of Science ®Google Scholar
• Martins ER, Andreu A, Melo-Cristino J, Ramirez M. Distribution of pilus islands in Streptococcus agalactiae that cause human infections: insights into evolution and implication for vaccine development. Clin Vaccine Immunol, 2013;20:313–6. doi:10.1128/CVI.00529-12.
   PubMed Web of Science ®Google Scholar
• Vengadesan K, Ma X, Dwivedi P, Ton-That H, Narayana SV. A model for group B Streptococcus pilus type 1: the structure of a 35-kDa C-terminal fragment of the major pilin GBS80. J Mol Biol. 2011;407:731–43. doi:10.1016/j.jmb.2011.02.024.
   PubMed Web of Science ®Google Scholar
• Khare B, Krishnan V, Rajashankar KR, H IH, Xin M, Ton-That H, Narayana SV. Structural differences between the Streptococcus agalactiae housekeeping and pilus-specific sortases: SrtA and SrtC1. PloS One. 2011;6:e22995. doi:10.1371/journal.pone.0022995.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Dwivedi P, Kim BJ, Samal A, Macon K, Ma X, Mishra A, Doran KS, Ton-That H, Narayana SV. Structure of Streptococcus agalactiae tip pilin GBS104: a model for GBS pili assembly and host interactions. Acta Crystallogr D Biol Crystallogr. 2013;69:1073–89. doi:10.1107/S0907444913004642.
   PubMedGoogle Scholar
• Banerjee A, Kim BJ, Carmona EM, Cutting AS, Gurney MA, Carlos C, Feuer R, Prasadarao NV, Doran KS. Bacterial Pili exploit integrin machinery to promote immune activation and efficient blood-brain barrier penetration. Nat Commun. 2011;2:462. doi:10.1038/ncomms1474.
   PubMed Web of Science ®Google Scholar
• Sheen TR, Jimenez A, Wang NY, Banerjee A, van Sorge NM, Doran KS. Serine-rich repeat proteins and pili promote Streptococcus agalactiae colonization of the vaginal tract. J Bacteriol. 2011;193:6834–42. doi:10.1128/JB.00094-11.
   PubMed Web of Science ®Google Scholar
• Konto-Ghiorghi Y, Mairey E, Mallet A, Dumenil G, Caliot E, Trieu-Cuot P, Dramsi S. Dual role for pilus in adherence to epithelial cells and biofilm formation in Streptococcus agalactiae. PLoS Pathog. 2009;5:e1000422. doi:10.1371/journal.ppat.1000422.
   PubMed Web of Science ®Google Scholar
• Nuccitelli A, Cozzi R, Gourlay LJ, Donnarumma D, Necchi F, Norais N, Telford JL, Rappuoli R, Bolognesi M, Maione D, et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against group B streptococcus infections. Proc Natl Acad Sci U S A. 2011;108:10278–83. doi:10.1073/pnas.1106590108.
   PubMed Web of Science ®Google Scholar
• Lin FY, Philips JB, 3rd, Azimi PH, Weisman LE, Clark P, Rhoads GG, Regan J, Concepcion NF, Frasch CE, Troendle J, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis. 2001;184:1022–8. doi:10.1086/323350.
   PubMed Web of Science ®Google Scholar
• Lin FY, Weisman LE, Azimi PH, Philips JB, 3rd, Clark P, Regan J, Rhoads GG, Frasch CE, Gray BM, Troendle J, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis. 2004;190:928–34. doi:10.1086/422756.
   PubMed Web of Science ®Google Scholar
• Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002; 51:717–22. doi:10.1099/0022-1317-51-9-717.
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for the serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol. 2006;13:165–9. doi:10.1128/CVI.13.2.165-169.2006.
   PubMed Web of Science ®Google Scholar
• Johnson SE, Rubin L, Romero-Steiner S, Dykes JK, Pais LB, Rizvi A, Ades E, Carlone GM. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis. 1999;180:133–40. doi:10.1086/314845.
   PubMed Web of Science ®Google Scholar
• Barrette RW, Urbonas J, Silbart LK. Quantifying specific antibody concentrations by enzyme-linked immunosorbent assay using slope correction. Clin Vaccine Immunol. 2006;13:802–5. doi:10.1128/CVI.00422-05.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol. 1998;5:479–85.
   PubMedGoogle Scholar
• Guttormsen H-K, Wetzler LM, Finberg RW, Kasper DL. Immunologic memory induced by a glycoconjugate vaccine in a murine adoptic transfer model. InfecImmun. 1998;66:2026–32.
   PubMed Web of Science ®Google Scholar
• Guttormsen HK, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J Infect Dis. 1996;173:142–50. doi:10.1093/infdis/173.1.142.
   PubMed Web of Science ®Google Scholar
• Bhushan R, Anthony BF, Frasch CE. Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent. InfectImmun. 1998;66:5848–53.
   PubMed Web of Science ®Google Scholar
• Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol. 2009;16:376–81. doi:10.1128/CVI.00344-08.
   PubMed Web of Science ®Google Scholar
• Coughlin RT, White AC, Anderson CA, Carlone GM, Klein DL, Treanor J. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine. 1998;16:1761–7. doi:10.1016/S0264-410X(98)00139-X.
   PubMed Web of Science ®Google Scholar
• Yu X, Gray B, Chang SJ, Ward JI, Edwards KM, Nahm MH. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis. 1999;180:1569–76. doi:10.1086/315096.
   PubMed Web of Science ®Google Scholar
• Yu X, Sun Y, Frasch CE, Concepcion N, Nahm MH. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol. 1999;6:519–24.
   PubMedGoogle Scholar
• Nahm MH, Olander JV, Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J Infect Dis. 1997;176:698–703. doi:10.1086/514093.
   PubMed Web of Science ®Google Scholar
• Nahm MH, Ward J, Chang S, Yu XH. Young children may produce antibodies against Streptococcus pneumoniae that are reactive but not opsonophagocytic to cross-reactive serotypes. ICAAC 1997:207(G-85).
   Google Scholar
• Fleck RA, Romero-Steiner S, Nahm MH. Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. A review. Clin Diagn Lab Immunol. 2005;12:19–27.
   PubMedGoogle Scholar
• Nahm MH, Briles DE, Yu X. Development of a multi-specificity opsonophagocytic killing assay. Vaccine. 2000;18:2768–71. doi:10.1016/S0264-410X(00)00044-X.
   PubMed Web of Science ®Google Scholar
• Kim KH, Yu J, Nahm MH. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol. 2003;10:616–21.
   PubMedGoogle Scholar
• Romero-Steiner S, Frasch C, Concepcion N, Goldblatt D, Kayhty H, Vakevainen M, Laferriere C, Wauters D, Nahm MH, Schinsky MF, et al. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2003;10:1019–24.
   PubMedGoogle Scholar
• Choi MJ, Noh JY, Cheong HJ, Kim WJ, Lin SM, Zhi Y, et al. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus. Hum Vaccin Immunother. 2018;14:67–73. doi:10.1080/21645515.2017.1377379.
   Google Scholar